Aadi Bioscience (NASDAQ:AADI) Stock

Aadi Bioscience

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

AADI

Biotech

News

Health Care

Financing

Offerings

Contracts

Movers

Trading Ideas

General

Aadi Bioscience secures ADC portfolio license, involving $44 million upfront and $805 million in milestones plus royalties.

Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?

FedEx.Shutterstock

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

American-Express-Platinum-credit-card

Downgrades

Markets

Analyst Ratings

This American Express Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Aadi Bioscience Inc

Press Releases

Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting

Aadi Bioscience to Participate in the Jefferies Healthcare Conference

Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update

Earnings

Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update

Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates

Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update

Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update

Aadi Bioscience Transforms with In-Licensing of Novel ADC Portfolio, $100 Million Sale of FYARRO® and $100 Million PIPE Financing

Small Cap

Aadi Bioscience Filed Definitive Proxy Statement and Schedules Special Meeting of Stockholders for February 28, 2025

Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer

Aligos Therapeutics

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Aerovate Therapeutics, Inc. - Common Stock

Aerovate Therapeutics

Avalo Therapeutics

bluebird bio

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BeyondSpring

Cibus

CytomX Therapeutics

Forte Biosciences

FibroGen

Gain Therapeutics

Genenta Science S.p.A. - American Depositary Shares

Genenta Science

IO Biotech

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

OncoCyte

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

PMV Pharma

Quince Therapeutics

Unicycive Therapeutics, Inc. - Common Stock

Unicycive Therapeutics

Exagen

Piper Sandler

Comments

Aadi Bioscience

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga